Sensex up 100 pts, Nifty above 9950; Dr Reddy’s Labs spikes 9%

Epic Update Dr Reddy's LabsEpic Update Dr Reddy's Labs

Dr Reddy’s Laboratories shares rallied more than 9 percent intraday after settlement agreement with US-based Vivus to resolve a long-pending patent litigation related to anti-obesity pill (or weight management capsules) Qsymia.

The settlement agreement permits the company to begin selling a generic version of Qsymia on June 1, 2025, or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia.

Qysmia is a combination of phentermine and topiramate extended-release sold in capsule form. The drug is used to manage chronic overweight in adults with obesity symptoms.

 The drug has gross sales of around USD 73.6 million in 2016.

For more information ✆ – 0731-6642300 or Visit http://www.epicresearch.co

Facebook Twitter YouTube Pinterest Linkedin Google+

You may also like:

Sensex, Nifty rangebound; RBI’s MPC meet outcome awaited' width= Sensex, Nifty continue to be sluggish ahead of RBI policy; Europe mixed' width=
Sensex, Nifty rangebound; RBI’s MPC meet outcome awaited Sensex, Nifty continue to be sluggish ahead of RBI policy; Europe mixed
Share Button

About the Author

Epic Research
Epic Research
Epic Research - Investment Adviser is a leading financial services provider with presence in Indian and other global capital markets. Call on - 0731-664-2300